MEDIVIR AB [CBOE] overview

MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 PR Newswire STOCKHOLM, April 30, 2024 STOCKHOLM , April 30, 2024 /PRNewswire/ -- Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January – March Financial summary for the quarter Net turnover amounted to SEK 0.5 (0.4) million. The loss before interest, tax, depreciation...

Medivir brings the Q1 webcast forward to 10 a.m. on April 30 PR Newswire STOCKHOLM, April 29, 2024 STOCKHOLM , April 29, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30 , at 10 a.m. CET . The webcast is brought forward as Nasdaq Stockholm closes earlier. For additional...

Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI PR Newswire STOCKHOLM, April 29, 2024 STOCKHOLM , April 29, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in hepatocellular carcinoma (HCC) has been accepted for presentation at...

FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease PR Newswire STOCKHOLM, April 25, 2024 STOCKHOLM , April 25, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR ) (STO: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation...

Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue PR Newswire STOCKHOLM, April 23, 2024 STOCKHOLM , April 23, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global phase 2b study...

Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701 PR Newswire STOCKHOLM, April 15, 2024 STOCKHOLM , April 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a...

Medivir to present at Investing in Oncology Forum on April 10 PR Newswire STOCKHOLM, April 9, 2024 STOCKHOLM , April 9, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Investing in Oncology Forum on April 10, 2024 . CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b /2a clinical study...

Medivir 2023 Annual Report published PR Newswire STOCKHOLM, April 4, 2024 STOCKHOLM , April 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company's website: www.medivir.com . In the fall of 2023, very promising data from the ongoing phase 1b /2a study with Medivir's spearhead project fostrox in combination with Lenvima ® were presented. The combination has shown continued improved clinical benefit in patients...